| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hannah Stocker, Andreas Nabers, Laura Perna, Tobias Möllers, Dan Rujescu, Annette M Hartmann, Bernd Holleczek, Ben Schöttker, Julia Stockmann, Klaus Gerwert, Hermann Brenne. Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer's disease. Translational psychiatry. vol 11. issue 1. 2021-06-28. PMID:33934115. |
alzheimer's disease is highly heritable and characterized by amyloid plaques and tau tangles in the brain. |
2021-06-28 |
2023-08-13 |
Not clear |
| Atsushi Michael Kimura, Mayumi Tsuji, Taro Yasumoto, Yukiko Mori, Tatsunori Oguchi, Yuya Tsuji, Masakazu Umino, Asami Umino, Toru Nishikawa, Shiro Nakamura, Tomio Inoue, Yuji Kiuchi, Masahito Yamada, David B Teplow, Kenjiro On. Myricetin prevents high molecular weight Aβ Free radical biology & medicine. vol 171. 2021-06-28. PMID:34015458. |
myricetin prevents high molecular weight aβ excessive accumulation of amyloid β-protein (aβ) is one of the primary mechanisms that leads to neuronal death with phosphorylated tau in the pathogenesis of alzheimer's disease (ad). |
2021-06-28 |
2023-08-13 |
Not clear |
| Kazutoshi Kasho, Lukas Krasauskas, Vytautas Smirnovas, Gorazd Stojkovič, Ludmilla A Morozova-Roche, Sjoerd Wanrooi. Human Polymerase δ-Interacting Protein 2 (PolDIP2) Inhibits the Formation of Human Tau Oligomers and Fibrils. International journal of molecular sciences. vol 22. issue 11. 2021-06-28. PMID:34071254. |
a central characteristic of alzheimer's disease (ad) and other tauopathies is the accumulation of aggregated and misfolded tau deposits in the brain. |
2021-06-28 |
2023-08-13 |
human |
| Jing Zhang, Na Wu, Shubo Wang, Zitong Yao, Fuchuan Xiao, Jing Lu, Baian Che. Neuronal loss and microgliosis are restricted to the core of Aβ deposits in mouse models of Alzheimer's disease. Aging cell. vol 20. issue 6. 2021-06-26. PMID:34080759. |
amyloid-β (aβ) deposits, pathologic tau, and neurodegeneration are major pathological hallmarks of alzheimer's disease (ad). |
2021-06-26 |
2023-08-13 |
mouse |
| Nalini Vijay Gorantla, Subashchandrabose Chinnathamb. Autophagic Pathways to Clear the Tau Aggregates in Alzheimer's Disease. Cellular and molecular neurobiology. vol 41. issue 6. 2021-06-25. PMID:32529542. |
autophagic pathways to clear the tau aggregates in alzheimer's disease. |
2021-06-25 |
2023-08-13 |
Not clear |
| Elizabeth C Mormino, Tyler N Toueg, Carmen Azevedo, Jessica B Castillo, Wanjia Guo, Ayesha Nadiadwala, Nicole K Corso, Jacob N Hall, Audrey Fan, Alexandra N Trelle, Marc B Harrison, Madison P Hunt, Sharon J Sha, Gayle Deutsch, Michelle James, Carolyn A Fredericks, Mary Ellen Koran, Michael Zeineh, Kathleen Poston, Michael D Greicius, Mehdi Khalighi, Guido A Davidzon, Bin Shen, Greg Zaharchuk, Anthony D Wagner, Frederick T Chi. Tau PET imaging with European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:32572562. |
tau pet imaging with in vivo measurement of the spatial distribution of neurofibrillary tangle pathology is critical for early diagnosis and disease monitoring of alzheimer's disease (ad). |
2021-06-25 |
2023-08-13 |
Not clear |
| Laetitia Lemoine, Per-Göran Gillberg, Nenad Bogdanovic, Inger Nennesmo, Laure Saint-Aubert, Matti Viitanen, Caroline Graff, Martin Ingelsson, Agneta Nordber. Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer's disease variants: AβPParc and PSEN1DE9. Molecular psychiatry. 2021-06-25. PMID:32581318. |
amyloid, tau, and astrocyte pathology in autosomal-dominant alzheimer's disease variants: aβpparc and psen1de9. |
2021-06-25 |
2023-08-13 |
Not clear |
| Mahsa Pourhamzeh, Mohammad Taghi Joghataei, Soraya Mehrabi, Reza Ahadi, Seyed Mohammad Massood Hojjati, Nasrin Fazli, Seyed Massood Nabavi, Hossein Pakdaman, Koorosh Shahpasan. The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally Pathogenic. Cellular and molecular neurobiology. vol 41. issue 6. 2021-06-25. PMID:32696288. |
alzheimer's disease (ad) is a neurodegenerative disorder, in which amyloid precursor protein (app) misprocessing and tau protein hyperphosphorylation are well-established pathogenic cascades. |
2021-06-25 |
2023-08-13 |
Not clear |
| Rik Ossenkoppele, Antoine Leuzy, Hanna Cho, Carole H Sudre, Olof Strandberg, Ruben Smith, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Tomas Olsson, Jonas Jögi, Erik Stormrud, Young Hoon Ryu, Jae Yong Choi, Adam L Boxer, Maria L Gorno-Tempini, Bruce L Miller, David Soleimani-Meigooni, Leonardo Iaccarino, Renaud La Joie, Edilio Borroni, Gregory Klein, Michael J Pontecorvo, Michael D Devous, Sylvia Villeneuve, Chul Hyoung Lyoo, Gil D Rabinovici, Oskar Hansso. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:33215319. |
a substantial proportion of amyloid-β (aβ)+ patients with clinically diagnosed alzheimer's disease (ad) dementia and mild cognitive impairment (mci) are tau pet-negative, while some clinically diagnosed non-ad neurodegenerative disorder (non-ad) patients or cognitively unimpaired (cu) subjects are tau pet-positive. |
2021-06-25 |
2023-08-13 |
human |
| Karine Provost, Leonardo Iaccarino, David N Soleimani-Meigooni, Suzanne Baker, Lauren Edwards, Udo Eichenlaub, Oskar Hansson, William Jagust, Mustafa Janabi, Renaud La Joie, Orit Lesman-Segev, Taylor J Mellinger, Bruce L Miller, Rik Ossenkoppele, Julie Pham, Ruben Smith, Ida Sonni, Amelia Strom, Niklas Mattsson-Carlgren, Gil D Rabinovic. Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:33398408. |
to compare rates of tau biomarker positivity (t-status) per the 2018 alzheimer's disease (ad) research framework derived from [ |
2021-06-25 |
2023-08-13 |
Not clear |
| Joseph Seemiller, Gérard N Bischof, Merle C Hoenig, Masoud Tahmasian, Thilo van Eimeren, Alexander Drzezg. Indication of retrograde tau spreading along Braak stages and functional connectivity pathways. European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:33462630. |
tau pathology progression in alzheimer's disease (ad) is explained through the network degeneration hypothesis and the neuropathological braak stages; however, the compatibility of these models remains unclear. |
2021-06-25 |
2023-08-13 |
Not clear |
| Gemma Salvadó, Michel J Grothe, Colin Groot, Alexis Moscoso, Michael Schöll, Juan Domingo Gispert, Rik Ossenkoppel. Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia. European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:33521872. |
to examine associations between the apoe-ε2 and apoe-ε4 alleles and core alzheimer's disease (ad) pathological hallmarks as measured by amyloid-β (aβ) and tau pet in older individuals without dementia. |
2021-06-25 |
2023-08-13 |
Not clear |
| Gérard N Bischof, Alessandra Dodich, Marina Boccardi, Thilo van Eimeren, Cristina Festari, Henryk Barthel, Oskar Hansson, Agneta Nordberg, Rik Ossenkoppele, Osama Sabri, B Frisoni G Giovanni, Valentina Garibotto, Alexander Drzezg. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:33590274. |
clinical validity of second-generation tau pet tracers as biomarkers for alzheimer's disease in the context of a structured 5-phase development framework. |
2021-06-25 |
2023-08-13 |
Not clear |
| A Leuzy, N J Ashton, N Mattsson-Carlgren, A Dodich, M Boccardi, J Corre, A Drzezga, A Nordberg, R Ossenkoppele, H Zetterberg, K Blennow, G B Frisoni, V Garibotto, O Hansso. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:33674895. |
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for alzheimer's disease in the context of a structured 5-phase development framework. |
2021-06-25 |
2023-08-13 |
Not clear |
| N J Ashton, A Leuzy, T K Karikari, N Mattsson-Carlgren, A Dodich, M Boccardi, J Corre, A Drzezga, A Nordberg, R Ossenkoppele, H Zetterberg, K Blennow, G B Frisoni, V Garibotto, O Hansso. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:33677733. |
the development of blood biomarkers that reflect alzheimer's disease (ad) pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests for dementia differential diagnosis and early detection. |
2021-06-25 |
2023-08-13 |
Not clear |
| Konstantinos Chiotis, Alessandra Dodich, Marina Boccardi, Cristina Festari, Alexander Drzezga, Oskar Hansson, Rik Ossenkoppele, Giovanni Frisoni, Valentina Garibotto, Agneta Nordber. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European journal of nuclear medicine and molecular imaging. vol 48. issue 7. 2021-06-25. PMID:33723628. |
clinical validity of increased cortical binding of tau ligands of the thk family and pbb3 on pet as biomarkers for alzheimer's disease in the context of a structured 5-phase development framework. |
2021-06-25 |
2023-08-13 |
Not clear |
| Eli J Cornblath, Howard L Li, Lakshmi Changolkar, Bin Zhang, Hannah J Brown, Ronald J Gathagan, Modupe F Olufemi, John Q Trojanowski, Danielle S Bassett, Virginia M Y Lee, Michael X Henderso. Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor. Science advances. vol 7. issue 24. 2021-06-25. PMID:34108219. |
neuropathological staging studies have suggested that tau pathology spreads through the brain in alzheimer's disease (ad) and other tauopathies, but it is unclear how neuroanatomical connections, spatial proximity, and regional vulnerability contribute. |
2021-06-25 |
2023-08-13 |
mouse |
| Meng-Shan Tan, Xi Ji, Jie-Qiong Li, Wei Xu, Hui-Fu Wang, Chen-Chen Tan, Qiang Dong, Chuan-Tao Zuo, Lan Tan, John Suckling, Jin-Tai Y. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia. Alzheimer's research & therapy. vol 12. issue 1. 2021-06-24. PMID:32393375. |
models of alzheimer's disease (ad) pathophysiology posit that amyloidosis [a] precedes and accelerates tau pathology [t] that leads to neurodegeneration [n]. |
2021-06-24 |
2023-08-13 |
Not clear |
| Caitlin N Suire, Samer O Abdul-Hay, Tomoko Sahara, Dongcheul Kang, Monica K Brizuela, Paul Saftig, Dennis W Dickson, Terrone L Rosenberry, Malcolm A Leissrin. Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40. Alzheimer's research & therapy. vol 12. issue 1. 2021-06-24. PMID:32631408. |
cathepsin d (catd) is a lysosomal protease that degrades both the amyloid β-protein (aβ) and the microtubule-associated protein, tau, and has been genetically linked to late-onset alzheimer disease (ad). |
2021-06-24 |
2023-08-13 |
Not clear |
| Kyu Hwan Shim, Min Ju Kang, Jee Won Suh, Jung-Min Pyun, Nayoung Ryoo, Young Ho Park, Young Chul Youn, Jae-Won Jang, Jee Hyang Jeong, Kyung Won Park, Seong Hye Choi, Kyoungho Suk, Ho-Won Lee, Pan-Woo Ko, Chan-Nyoung Lee, Tae-Sung Lim, Seong Soo A An, SangYun Ki. CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation. Alzheimer's research & therapy. vol 12. issue 1. 2021-06-24. PMID:32660565. |
csf total tau/α-synuclein ratio improved the diagnostic performance for alzheimer's disease as an indicator of tau phosphorylation. |
2021-06-24 |
2023-08-13 |
Not clear |